Abstract
Nephronophthisis is a chronic tubulointerstitial nephritis with autosomal recessive inheritance whose evolution to end-stage renal disease is insidious but constant. Fibrous dysplasia of bone is characterized by focal replacement of normal bone and marrow with abnormal bone and fibrous tissue. We report on a young boy initially diagnosed with fibrous dysplasia of bone, who underwent renal investigation because of treatment with pamidronate. He presented with mild proteinuria (albuminuria/creatininuria 19 mg/mmol) and decreased glomerular filtration rate (GFR) (79 ml/min per 1.73 m2 body surface area) leading to kidney biopsy, which showed nephronophthisis-like lesions, but neither NPHP1 gene deletion nor UMOD (uromodulin) mutation were identified. No association between fibrous dysplasia of bone and nephronophthisis has yet been described. Nephronophthisis-like nephritis associated with fibrous dysplasia of bone might represent a possible new syndrome in the nephronophthisis and medullary cystic kidney disease complex. However, a fortuitous association between these two conditions is also possible.
This is a preview of subscription content, log in via an institution to check access.
References
Niaudet P, Salomon R (2006) Nephronophtisis. Nephrol Ther 2:200–206
Hildebrandt FR (2002) Nephronophthisis and related diseases. In: Cochat P (ed) European society of pediatric nephrology handbook. Lyon, Medcom, pp 201–207
DiCaprio MR, Enneking WF (2005) Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am 87:1848–1864
Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M (2004) Minireview: GNAS: normal and abnormal functions. Endocrinology 145:5459–5464
Zacharin M, O’Sullivan M (2000) Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 137:403–409
Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ (2004) Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 35:235–242
Chapurlat R (2005) Current pharmacological treatment for fibrous dysplasia and perspectives for the future. Joint Bone Spine 72:196–198
Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C (2000) Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 89:188–193
Chattopadhyay A, Bhansali A, Mohanty SK, Khandelwal N, Mathur SK, Dash RJ (2003) Hypophosphatemic rickets and osteomalacia in polyostotic fibrous dysplasia. J Pediatr Endocrinol Metab 16:893–896
Dent CE, Gertner JM (1976) Hypophosphataemic osteomalacia in fibrous dysplasia. Q J Med 45:411–420
Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG (2001) Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 16:806–813
Forest M (1988) Fibrous dysplasia. In: Forest M, Tomeno B, Vanel D (eds) Orthopedic surgical pathology. London, Churchill Livingstone, pp 595–612
Han BK, Babcock DS (1985) Sonographic measurements and appearance of normal kidneys in children. AJR Am J Roentgenol 145:611–616
Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, Goto H, Ohashi H, Koyano HM, Mochizuchi R, Miki T, Inaba M, Nishizawa Y (2006) Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci 78:2295–2301
Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692
Riminucci M, Saggio I, Robey PG, Bianco P (2006) Fibrous dysplasia as a stem cell disease. J Bone Miner Res 21(Suppl 2):125–131
Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D’Agati VD (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164–1172
Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z (2004) Pamidronate-induced nephrotoxic tubular necrosis—a case report. Clin Nephrol 61:63–67
Sauter M, Julg B, Porubsky S, Cohen C, Fischereder M, Sitter T, Schlondorff D, Gröne HJ (2006) Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 47:1075–1080
Janssen van Doorn K, Neyns B, Van der Niepen P, Verbeelen D (2001) Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron 89:467–468
Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M (2006) Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29:534–540
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bacchetta, J., Chapurlat, R., Bouvier, R. et al. Nephronophthisis-like nephritis associated with fibrous dysplasia of bone. Pediatr Nephrol 23, 1559–1563 (2008). https://doi.org/10.1007/s00467-008-0850-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-008-0850-x